ArticleFrontiers in oncology2026
Bilateral multifocal nephrogenic adenomas arising in the renal pelves: a case report and review of the literature.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Nephrogenic adenoma (NA) is a benign epithelial lesion of the genitourinary tract resulting from the reimplantation and proliferation of exfoliated renal tubular cells at sites of urothelial injury. It most commonly arises in the bladder, while involvement of the renal pelvis is exceedingly rare. Bilateral multifocal presentation with atypical histologic features has not been previously reported. Case presentation: A 50-year-old male with a history of bladder stone lithotripsy presented with painless gross hematuria and lumbodorsal aching of nine months' duration. Preoperative workup included three urine cytology examinations, which showed atypical cells suspicious for malignancy, and an outside hospital biopsy of the left renal pelvis. Review of the biopsy at our institution revealed no definitive malignant components (the specimen contained renal parenchyma, fibromuscular tissue, and scant urothelium with chronic inflammation), rendering the diagnosis indeterminate. Ultrasonography revealed bilateral multiple renal calculi and multiple solid masses in the bilateral renal collecting systems, suggestive of bilateral renal pelvic carcinoma. Given the bilateral disease and diagnostic uncertainty, the patient underwent staged percutaneous nephroscopic tumor resections. The right-sided lesion showed NA with focal atypia (CK7+, PAX8+, P504S+, CK20-, GATA-3-, Ki-67 ~10%). Two months later, the patient was readmitted for left-sided lesions. Non-contrast computed tomography (CT) demonstrated multiple nodular and strip-like lesions at the left renal pelvis and ureteropelvic junction, with the largest measuring 14 × 8 mm, accompanied by mild dilatation of the left pelvicalyceal system. Left percutaneous nephroscopic tumor resection was performed, and pathology confirmed atypical NA (PAX8+, EMA+, TFE3+, focal CK7/CK20/P504S/CAIX+, Ki-67 ~10%, p53 patchy ~80%). Specimens were fragmented, precluding margin assessment, though no macroscopic residual tumor was observed intraoperatively. Follow-up at 10 months showed no recurrence or metastasis. Conclusion: This is the first report of bilateral multifocal NA arising in the renal pelvis with atypical histologic features and an elevated Ki-67 proliferation index. This case expands the known morphological spectrum of NA and highlights important diagnostic challenges. Urologists and pathologists should be aware of this rare entity to avoid misdiagnosis as bilateral renal pelvic carcinoma and subsequent overtreatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.